Role of Yes-Associated Protein (YAP) in Liver Injury and Regeneration following Acetaminophen Overdose by Poudel, Samikshya
 
 




  Samikshya Poudel 
Submitted to the graduate degree program in Toxicology and the Graduate Faculty of the 
University of Kansas Medical Center in partial fulfillment of the requirement for the degree of 













Date Defended:  August 2, 2016 
Chairperson: Udayan Apte, PhD, DABT 
Michele Pritchard, PhD 
Hartmut Jaeschke, PhD 
ii 
 




















Date approved: August 2, 2016 





Acetaminophen (APAP) overdose is the major cause of Acute Liver Failure (ALF) in the 
Western world. Treatment options for APAP-induced ALF are limited. Studies have 
shown that stimulating liver regeneration could be a potential treatment for ALF after 
APAP overdose. However, the mechanisms of liver regeneration after APAP overdose 
are not completely understood, which is the focus of research in our laboratory. We 
investigated the role of Yes-associated protein (YAP), the downstream co-activator of 
Hippo Signaling Pathway, in liver injury and regeneration following APAP overdose. 
Previous studies have shown that YAP is involved in stimulation of hepatocyte 
proliferation during postnatal liver growth, regeneration after partial hepatectomy and 
during liver cancer pathogenesis. Treatment of two-three month old C57BL/6J male 
mice with 300 mg/kg APAP (APAP 300) resulted in significant liver injury and 
regeneration over a time course of 0 to 96 hr. Increased activation of YAP was 
observed during initial time points (3, 6 and 12 hr) after APAP administration which 
coincided with both injury and regeneration. To determine whether YAP activation plays 
a role in injury or regeneration, we generated hepatocyte specific YAP knockout mice 
(hYAP-KO) by treating two-three month old male YAP-floxed mice with AAV8.TGB.Cre. 
Hepatocyte specific deletion of YAP neither caused liver injury, nor did it change hepatic 
CYP2E1 expression and hepatic glutathione (GSH) levels. Consistent with these data, 
no difference in APAP-protein adducts was observed between control and hYAP-KO 
mice after APAP treatment. Liver injury measured by serum ALT and histopathology 
showed extensive and similar liver injury up to 12 hr after APAP treatment in both 
control and hYAP-KO mice. However, the progression of the liver injury beyond 12 hr 
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after APAP administration was significantly lower in hYAP-KO mice as compared to 
control mice. The decrease in progression of liver injury was accompanied with an 
earlier decrease in JNK activation and faster GSH recovery.  Additionally, the hYAP-KO 
mice showed an early induction of proliferative markers demonstrating early liver 
regeneration as compared to the control mice. These data indicate that hepatocyte 
specific activation of YAP may be involved in progression of liver injury. Linked to that, 
hepatocytes specific deletion of YAP results in earlier onset of regeneration after APAP 
overdose. These findings indicate a differential role of YAP in APAP overdose and 
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Acetaminophen (APAP) Overdose and Hepatotoxicity 
Acetaminophen (APAP) is a safe analgesic and antipyretic over-the-counter drug1.  
Whereas it is safe at therapeutic doses, overdose of APAP causes severe hepatic 
necrosis leading to acute liver failure (ALF). APAP-induced ALF is the most common 
cause of ALF in the United States2, 3. The reasons for APAP overdose are suicide 
attempts with the drug and unintentional therapeutic misadventures during treatment for 
pain and fever exceeding the recommended 4g/day dose2. There are an estimated 
60,000 emergency visits and 26,000 hospitalizations yearly associated with APAP 
overdoses, with most cases being intentional overdose. Nearly 500 patients die of the 
overdose annually, and about 20% death occur with unintentional APAP overdose4. The 
most common treatment option available at present is N-acetylcysteine (NAC), which 
replenishes glutathione levels if administered within 12 hours of the overdose2, 5. The 
other option is liver transplantation, which is complicated by donor availability, donor 
and recipient age, donor and recipient ABO mismatching, high costs and post-
transplantation psychological issues6, 7. 
 The mechanisms of APAP induced hepatotoxicity have been studied in rodent 
models for over four decades8-10. When a therapeutic dose of APAP is taken, the 
majority of the dose (about 70-80%) is glucuronidated or sulfated and then excreted. A 
small percentage (about 5-10 %) of APAP is metabolized by cytochrome P450 enzymes 
to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI). NAPQI conjugates 
with the cellular nucleophile glutathione (GSH) and is then excreted10, 11. The higher 
doses saturate the conjugation pathways, resulting in the formation of excessive 
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NAPQI. The excess NAPQI lowers the GSH levels and binds with the cellular proteins, 
especially mitochondrial proteins, forming adducts12, 13. NAPQI binding to mitochondrial 
proteins leads to oxidative stress in mitochondria, which ultimately results in the 
phosphorylation and activation of the c-jun N-terminal kinase (JNK). The activated JNK 
then translocate to the mitochondria resulting in amplification of the oxidative stress14. 
JNK does not seem to be directly activated by early events of APAP toxicity. A number 
of upstream kinases have been identified, which have shown to activate JNK. These 
kinases include apoptosis signal-regulating kinase 1 (ASK1), glycogen synthase kinase-
3β (GSK-3β), mixed-lineage kinase 3 (MLK 3), receptor interacting protein kinase (RIP) 
1 and RIP315. The extensive oxidative stress results in the opening of mitochondrial 
membrane permeability transition (MPT) pore and release of apoptosis inducing factor 
(AIF) and endonuclease G (EndoG) from mitochondria16, 17. These proteins translocate 
to the nucleus causing nuclear DNA fragmentation, ultimately leading to necrotic liver 
cell death18 (Fig.1). 
 
Mechanisms of Regeneration following APAP overdose 
The liver has a remarkable capacity to regenerate after drug-induced injury. It is known 
that liver regeneration is a critical determinant of final outcome, i.e. survival or death, 
after drug overdose19. A previous study has shown an increase in alpha-fetoprotein 
(AFP) in surviving patients with APAP- induced liver injury, which is considered an 
indicator of liver regeneration20. Studies of liver regeneration in mouse models suggest 
stimulating liver regeneration improves survival after APAP overdose in mice21, 22. 
These studies indicate that stimulating liver regeneration could be the therapeutic option 
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in the treatment of APAP -induced ALF. The mechanisms of liver regeneration have 
been studied mainly using partial hepatectomy or relatively less following toxicant-
induced injury with carbon tetrachloride, chloroform and thioacetamide or drug induced 
liver injury with acetaminophen21-23.  Specifically, the mechanisms of liver regeneration 
after APAP-induced ALF are not completely understood22.  
 
 
                        Modified from: McGill…Jaeschke et al. Toxicol Appl Pharmacol 2013; 264(3): 387-394                                                                                                                                                                               
 
Figure 1: Mechanism of APAP metabolism and toxicity, and compensatory liver regeneration 
The therapeutics dose of APAP is glucuronidated and sulfated and excreted from the body. The reactive 
metabolite NAPQI formed from the metabolism of APAP is conjugated with glutathione and excreted. 
However, the toxic/overdose of APAP saturates the conjugation pathway leading to excessive 
accumulation of NAPQI, which binds, with the mitochondrial protein increasing the oxidative stress in 
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mitochondria. The increased oxidative stress phosphorylates and activates JNK and leads to its 
mitochondrial translocation. The activated JNK further amplifies oxidative stress leading to the opening 
MPT pore and release of AIF and EndoG. These proteins translocate to the nucleus causing nuclear DNA 
fragmentation and ultimately leading to necrotic cell death. Liver has remarkable capacity to regenerate. If 
the regeneration is impaired, it leads to acute liver failure (ALF). However, if regeneration follows, then it 
leads to recovery. 
  
Role of cytokines and growth factors have been studied in liver regeneration 
following APAP induced hepatotoxicity. Tumor necrosis factor -α (TNF-α) mediated 
proliferative signaling in hepatocytes is majorly mediated by TNF receptor 1 (TNFR1). 
Deletion of TNFR1 results in decreased liver regeneration after APAP overdose in 
mice24. TNF-α binds to its receptor leading to stabilization and nuclear translocation of 
the transcription factor NF-B. Reduced NF-B DNA binding is associated with reduced 
liver regeneration in mice25. Similarly, IL-6 also plays a significant role in regeneration 
after APAP-induced liver injury. Impairment of liver regeneration is seen in IL-6 
knockout mice shown by decreased PCNA positive cells. However, pre-treatment of the 
knockout mice with IL-6 restores the regeneration26. These studies show that cytokines 
are essential for the liver regeneration following APAP overdose.  
 The epidermal growth factor (EGF) and hepatocyte growth factor (HGF), which 
act through phosphorylation or activation of EGF receptor (EGFR) and c-Met receptor 
respectively, are critical for liver regeneration after PH23. However, administration of 
TGF-α (ligand of EGFR) along with other hepatic stimulatory substances and liver 
growth factors in beagle dogs did not affect survival or regeneration following lethal 
dose of APAP27. The other study shows elevated plasma level of HGF in the non-
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surviving APAP- induced ALF patients28. These studies show that EGF and HGF may 
not be beneficial for liver regeneration after APAP overdose and additional studies are 
required to elucidate additional mechanisms of liver regeneration after APAP overdose. 
In contrast to EGF and HGF, vascular endothelial growth factor (VEGF) is important in 
liver regeneration after APAP overdose. Expression of VEGF and its receptors 
(VEGFR1, VEGFR 2, and VEGFR 3) increase after APAP overdose in mice. In addition, 
treatment with a VEGF inhibitor decreases regeneration in those mice after APAP 
overdose showing the advantageous role of VEGF in liver regeneration29.  
A novel incremental dose model has been developed in our laboratory to provide 
insight into several signaling pathways that are involved in liver regeneration after APAP 
overdose. In this model, liver injury and regeneration were compared over a time course 
after administration of 300 mg/kg APAP (APAP 300) and 600 mg/kg APAP (APAP 600) 
in mice. After APAP 300, liver injury was followed by regeneration. By contrast, after 
APAP 600, liver injury persisted over the time course. Hence, APAP 300 was defined as 
the regenerative dose and APAP 600 as the non- regenerative dose22. This model 
revealed that the canonical Wnt/ β-catenin signaling pathway is one of the main 
pathways involved in liver regeneration after APAP overdose. The pathway was 
stimulated in the regenerative dose and was inhibited in the non- regenerative dose, 
suggesting the reason for the inhibited regeneration at the higher APAP dose. The 
inhibition of Wnt/ β -catenin pathway was evident by decreased nuclear localization of 
β-catenin and substantial increase in the two inactive forms of β-catenin (Ser45/Thr41 
phosphorylated and Ser33/37/Thr41 phosphorylated). The non-phosphorylated or active 
form of glycogen synthase kinase-3β (GSK3β) regulates β-catenin degradation, and its 
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expression was increased at the higher dose or the non- regenerative dose. 
Additionally, liver regeneration was increased in β- catenin overexpressing mice 
following APAP overdose showing the potential role of β-catenin in regeneration22. 
 
Hippo Signaling Pathway 
The Hippo signaling pathway is highly conserved from Drosophila to mammals and is 
involved in the regulation of organ size30. Yes-associated protein (YAP) is the 
downstream transcriptional coactivator of the Hippo signaling pathway (Fig. 2). The 
Hippo pathway consists of two serine/threonine kinases Mst1/2 and LATS1/2, both of 
which act upstream of YAP. Activated Mst phosphorylates and activates LATS kinase. 
The activated LATS then phosphorylates YAP at serine 127. Once phosphorylated, 
YAP is inactive and is targeted for 14-3-3 mediated degradation in the cytoplasm. 
However, when the pathway is inactive, YAP is not phosphorylated by upstream protein 
kinases. The non-phosphorylated-active YAP enters the nucleus, associates with the 
transcription factor TEAD and initiates the transcription of genes involved in cell 
proliferation and survival30, 31.   
Upstream regulators of the Hippo pathway remain elusive. Studies have 
implicated several proteins including NF2/Mer, Fat cadherin and G-protein coupled 
receptors as upstream regulators32-34. Increased nuclear YAP and elevated YAP protein 
level is observed in liver specific NF2 knockout mice. The activity of LATS 1/2 is also 
reduced in these NF2 deficient mice showing that NF2 acts upstream and regulates the 




Figure 2: Hippo Signaling Pathway 
In the on state, the upstream proteins of the Hippo pathway are active and hence phosphorylates YAP 
leading to its degradation in cytoplasm. However, in the off state, YAP is in its active form which enters 
the nucleus, binds with TEAD and initiates the transcription of genes involved in anti-apoptosis and 
proliferation.  
 
epithelial cells of the drosophila imaginal disc, was also shown to regulate the Hippo 
pathway. Mutation in fat (ft) cadherin in drosophila imaginal disc results in the increased 
size of the disc. The disc size is even greater in a ft homozygous and wts (LATS 1/2 
ortholog in drosophila) heterozygous double mutant. However, the size of the disc is 
suppressed and returns back to the size of wild type disc when one copy of yki 
(drosophila ortholog of YAP) is also mutated in the ft mutant. This change in the disc  
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size explains that Fat controls organ size by modulating the activity of the Hippo 
pathway34. It has also been shown that the Hippo pathway acts downstream of G-
protein coupled receptor (GPCR). Overexpression of GPCRs that mainly activate Gs 
signaling induce YAP/TAZ phosphorylation. Also, activation of Gs-coupled receptor, by 
epinephrine or glucagon stimulation, increases LATS 1/2 activity and inhibits YAP 
function showing GPCR as the modulator of the Hippo pathway32. 
 
Roles of YAP in Pathophysiology 
Studies have shown the roles of YAP in organ size control, liver development, 
regeneration, stem cell function and cancer development31, 35-37. The overexpression of 
Yorki (Yki, the drosophila ortholog of YAP) in the imaginal disc of the fly during 
development results in the massive increase in the size of the wing. This overgrowth 
results because the cells overexpressing Yki multiply faster than the wild-type cells. 
There is no acceleration of the particular phase of the cell-cycle after Yki 
overexpression; each phase is proportionally accelerated38. Similarly, overexpression of 
YAP in a normal mouse liver without surgical resection or injury results in massive 
hepatomegaly because of an increase in cell number, not the cell size31.  
The liver undergoes a maturation process following birth. The proliferation, 
differentiation of liver, and expression of an adult genes, several drug metabolizing 
enzymes, transporters and other enzymes involved in the metabolic process occur 
during the postnatal liver development period36, 39. This process takes about 30 days in 
rodents and up to 5 years in humans40. The involvement of YAP in postnatal liver 
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development has been studied36. The activation of YAP and increased proliferation are 
observed during postnatal liver development in mice. Also, the partial deletion of YAP in 
mice results in decreased liver to body weight ratio and decreased proliferation during 
the postnatal period. These findings demonstrate that YAP stimulates cell proliferation 
and is involved in hepatic differentiation during postnatal liver development36. 
 The mammalian liver has tremendous capacity to regenerate. Following partial 
hepatectomy (PH), in which approximately 60% to 70% of the liver is removed, the 
remaining liver regenerates and restores lost liver mass after 5-7 days by proliferation of 
all the existing mature cellular populations41. Involvement of the Hippo signaling 
pathway has been studied during liver regeneration following PH35. During the 
regeneration period, the expression level of YAP is increased, its inactive form (p-YAP) 
is decreased and its nuclear localization is increased showing the activation of YAP. 
Also, YAP target genes, including CTGF, AmotL2 and Cyr61, are also increased. These 
results support the involvement of YAP during liver regeneration after PH35. The 
proliferation of mature hepatocytes is sufficient for regeneration after acute liver injury. 
However, during conditions of extreme stress and chronic injury, hepatic progenitor cells 
(HPCs), which are also called “oval cells”, undergo proliferation and differentiation to 
restore the liver mass42,43. The expression and activation of YAP is higher in biliary cells 
than in hepatocytes, shown by the increased nuclear localization of YAP in bile ducts. 
Overexpression of YAP in biliary cells results in hyperplasia, with no activation or 
appearance of HPCs44. However, overexpression of YAP in hepatocytes can 
transdifferentiate them into HPCs. High levels of YAP in hepatocytes alters the fate of 
about 75% of the adult hepatocytes which develop into HPCs. In addition, when YAP 
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overexpression is ceased after the hepatocytes differentiate into HPCs, the HPCs 
redifferentiate into cells of the hepatocyte lineage44. These findings suggest that 
overexpressing YAP in hepatocytes of chronically injured liver could accelerate the 
recovery of the lost liver mass.  
 Because YAP plays a critical role in the regulation of organ size and 
regeneration, it must have potent growth promoting activity. Indeed, overexpression of 
YAP is observed in various forms of cancer: lung, ovarian, pancreatic, colorectal, 
hepatocellular, and prostate carcinomas31, 37.  Specific to hepatic malignancies, 
hepatocellular carcinoma (HCC), hepatoblastoma (HB) and cholangiocarcinoma (CC) 
are the three different types of tumors that arise from the liver cells45. HCC is the sixth 
most common cancer worldwide and the incidence is attributed mostly to the Hepatitis B 
or C Virus (HBV/ HCV)46. Increased YAP expression is seen in samples of HBV- 
induced HCC and HBV-infected cell lines47. Similarly, elevated YAP expression and its 
nuclear localization is observed in HCC cell lines48. Furthermore, induction of YAP in 
mice results in uniform liver expansion initially and then results in hyperplastic nodule 
formation throughout the hepatic parenchyma. The nodules are composed of 
proliferative hepatocytes and display features of HCC31.  HB is the most frequent 
pediatric liver tumor and exhibits significant activation of YAP48. CC is the cancer that 
originates from the cholangiocytes of the intra- and extrahepatic biliary tract system. 
Overexpression of YAP and its nuclear localization is observed in CC cells and human 
samples48, 49. Silencing YAP inhibits CC tumorigenesis and metastasis, while 
overexpressing YAP promotes CC tumorigenesis and metastasis both in vivo and in 
vitro49. Thus, downregulating YAP could reduce liver tumor formation and metastasis. A 
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small molecule inhibitor called verteporfin has been discovered, which prevents the 
physical association between YAP and TEAD by selectively binding to YAP and 
changing its conformational structure to prevent any interaction with TEAD. Decreased 
liver size is observed in the YAP transgenic mice after verteporfin administration, 
demonstrating the potential use of verteporfin in patients with HCC50.  
 In summary, YAP is involved in regulation of organ size in Drosophila as well as 
in mouse liver31, 38.  YAP is also considered a candidate oncogene in multiple forms of 
human cancers51. Additionally, activation of YAP is shown in liver regeneration after 
partial hepatectomy35. However, the role of the Hippo Kinase pathway and YAP in liver 
injury and subsequent regeneration after APAP overdose is not known; this was the 
focus of my studies. Based on the previous studies, I hypothesized that YAP promotes 
liver regeneration following APAP overdose, and this was tested as defined briefly in the 










Specific Aim 1: To Determine the role of YAP in liver injury and regeneration after 
300 mg/kg APAP treatment. 
Based on the previous findings, I hypothesized that YAP promotes liver regeneration 
following APAP overdose. To test my hypothesis, we determined activation of YAP and 
induction of its target genes: AmotL2 and CTGF following treatment of 300 mg/kg APAP 
(APAP 300) in mice.  
 
Specific Aim 2: To Evaluate the effect of hepatocyte specific deletion of YAP on 
liver injury and regeneration after APAP overdose. 
To confirm the role of YAP, we generated hepatocyte specific YAP KO mice by treating 
two-three months old male YAP fl/fl mice with AAV8.TBG.PI.Cre.rBG virus (hYAP-KO) 
and AAV8.TBG.PI.eGFP.WPRE.bGH (Control). We then tested the effect of virus on 
the liver and effect of YAP deletion on the components of APAP metabolism pathway. 
We also observed liver injury, APAP metabolism pathway and liver regeneration in the 









Materials and Methods 
Animals, Treatments, and Tissue Collection 
Two to three month old male C57BL/6J mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). YAP floxed/floxed (YAP fl/fl) mice were generated by 
the NIH supported Knockout Mouse Project (KOMP) at the University of California Davis 
and were on the C57BL/6J background. All animals were housed in an Association for 
Assessment and Accreditation of Laboratory Animal Care-accredited facilities at the 
University of Kansas Medical Center (KUMC) under a standard 12 hour light-dark cycle 
with access to chow and water ad libitum. All studies were approved by the Institutional 
Animal Care and Use Committee at KUMC.  
 
Generation of Hepatocyte specific YAP KO mice (hYAP-KO): hYAP-KO mice were 
generated using Cre-LoxP technology. Two to three month old male YAP fl/fl mice (n= 
3-5) were treated with either AAV8.TBG.PI.Cre.rBG virus (hYAP-KO) or the 
AAV8.TBG.PI.eGFP.WPRE.bGH (Control mice) purchased from University of 
Pennsylvania Vector Core. The AAV8.TBG.PI.Cre.rBG (2.5 * 1011 viral particles) and 
AAV8.TBG.PI.eGFP.WPRE.bGH  (2.5 * 1010 viral particles) were diluted in 200µl of 
sterile 1X PBS and injected into YAP fl/fl mice intraperitoneally as described 





Acetaminophen (APAP) overdose experiments: Mice (n= 3-5) were fasted 12 hours 
before APAP administration. APAP was dissolved in warm 0.9% saline, and mice were 
treated with 300 mg/kg APAP intraperitoneally. Food was returned to the mice after one 
hour of APAP treatment. Mice were sacrificed at 0, 3, 6, 12, 24, 48, 72 and 96 hours 
after APAP administration by cervical dislocation under isoflurane anesthesia22. The 
YAP fl/fl mice were treated with 300 mg/kg APAP after 7 days of virus treatment and 
were sacrificed at 0, 1, 12, 24 and 48 hours after APAP treatment. Blood and livers 
were collected. Serum samples were obtained by centrifuging blood at 5000 rpm for 10 
minutes at 4°C and used for analysis of alanine aminotransferase (ALT) activity. The 
liver tissue was frozen in liquid N2 and stored at −80°C until it was used to isolate RNA 
and to prepare total cell extracts. 
 
Protein Isolation and Western Blot Analysis 
Total protein isolated from liver tissues using RIPA buffer [1% SDS, 20mM Tris-HCl (pH 
7.5), 150mM NaCl, 0.5% NP-40, 1% Triton X-100, and 0.25% sodium deoxycholate]. 
Cocktail of protease and phosphatase inhibitors (Halt Protease and Phosphatase 
Inhibitor Cocktail with EDTA: Thermo Fisher Scientific) was added at a concentration of 
1:100 to the RIPA buffer before use. 
 
Protein concentration of the lysates was determined using the bicinchoninic acid (BCA) 
protein assay reagent (Thermo Fisher Scientific). Total proteins (50 µg) were separated 
by electrophoresis on 4-12% NuPage Bis-Tris gels with MOPS buffer (Invitrogen, 
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Carlsbad, CA), then transferred to Immobilon-P membranes (Millipore) in NuPAGE 
transfer buffer containing 20% methanol. Membranes were stained with Ponceau S to 
verify loading and transfer efficiency. Membranes were then probed with primary and 
secondary antibodies in Tris-buffered saline with Tween 20 containing either 5% nonfat 
milk or 5% bovine serum albumin depending upon the antibody used. The signal was 
visualized by incubating the blots in SuperSignal West Pico Chemiluminescence 
Substrate (Thermo Fisher Scientific) and exposing to X-ray film (MidSci, St. Louis, MO). 
All antibodies used for Western analysis are listed in Table 1. 
 
Histology and immunohistochemistry (IHC) 
Paraffin-embedded liver sections (4 μm thick) were used. Slides were stained with 
hematoxylin and eosin (H &E) to observe necrosis in liver sections using an autostainer 
(model CV 5030, Leica Microsystems, Buffalo Grove, IL). 
 Paraffin sections were also stained with proliferating cell nuclear antigen (PCNA) (Cell 
Signaling, Catalog# 2586) to detect cell proliferation and YAP antibody (1:25 dilution) 
(Cell Signaling, Catalog# 4912). Antigen retrieval was achieved by the citrate buffer 
method. Slides were placed in boiling citrate buffer for 5 mins followed by incubation at 
sub-boiling temperature for 10 mins. The tissues were then blocked with 5% normal 
goat serum for 1 hr. Then the tissues were incubated with the primary antibody 
overnight at 4°C. The next day, the primary antibody was linked to a biotinylated 
secondary antibody followed by amplification using the routine avidin-biotin complex 
method (ABC Vectastain kit: Vector laboratories, Burlingame, CA). Diaminobenzidine 
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(DAB) was used as the chromogen, which resulted in a brown reaction product which 
precipitated on to the tissue surface.  
 
Real- Time PCR 
RNA was isolated from frozen liver tissues using the Trizol method according to the 
manufacturer’s protocol (Sigma, St. Louis, MO). mRNA for various genes were 
quantified using SYBR Green method on a real-time PCR system (model 7300, Applied 
Biosystems, Foster City, CA). RNA concentration was measured by spectrophotometry 
and samples were diluted to 0.1 µg/µl. cDNA was made using 1 µg of RNA per sample 
using M-MuLV Reverse transcriptase enzyme (Invitrogen, Carlsbad, CA) in a reverse 
transcription (RT)-mastermix containing random primers, 5× RT buffer, dNTP mix, 
RiboLock, and M-MuLV Reverse transcriptase enzyme. Analysis of cDNA was done 
using SYBR Green technology on a real-time PCR system (Applied Biosystems). 18S 
gene was used as an internal control. The Ct value of the 18S and the gene of interest 
obtained from the PCR system were used to calculate dCt value. ddCt values for each 
time points were then calculated subtracting mean dCt value of 0 hr of the respective 
group from that time point dCt value. Fold change was then measured using the formula 
2-ddCt. All samples were used in triplicate. All primers are obtained from Integrated DNA 






Table 1: List of antibodies used for Western blot analysis 
 
 







APAP protein adducts  
APAP protein adducts were measured in Dr. Hartmut Jaeschke’s laboratory using high 




ALT and Glutathione measurement 
ALT in serum was measured by using ALT (GPT) kit (ThermoFisher Scientific, 
Pittsburg, PA) and total glutathione in the liver tissues were measured by using 
Glutathione Assay Kit (Sigma Life Science).  
 
Statistical Analysis 
All results were expressed as mean ± SE. Comparison between multiple groups were 
performed using one-way ANOVA and between two groups were performed using 






Activation of YAP in APAP 300 
After APAP 300, there is an increase in liver injury until 12 hours, after which there is 
regression of injury and complete recovery by 72 and 96 hours (Fig. 3A). The hepatic 
cells enter the cell cycle and divide in response to liver injury, which was studied using 
PCNA analysis (Fig. 3B)22. We first examined the activation of YAP over the time course 
following treatment of 300 mg/kg APAP. The activation of YAP was studied using the 
Western blot analysis of total YAP and p-YAP. Additionally, immunohistochemical 
staining of YAP on liver sections was performed. A ratio of densitometric analysis of 
Western blot data on YAP to p-YAP was used as a measure of YAP activity. Western 
blot analysis indicated that YAP activity was unchanged during the initial time points and 
the change was seen at 72 hours after APAP treatment (Fig. 3, C and D). In IHC 
staining, YAP was mostly localized in the nucleus of biliary cells at 0 hr. At 3, 6 and 12 
hours, YAP was localized in the nucleus of both biliary and hepatic cells suggesting 
increased activation of YAP at these time points. The nuclear localization of YAP 
decreased while cytoplasmic localization increased at 24,48 and 72 hours. These data 
suggest YAP activation was reduced at these time points after APAP-induced liver 
injury. When the hepatic cells are completely recovered at 96 hours, YAP was localized 
in the biliary compartments, similar to the 0 hour time point (Fig. 4). Next, we looked at 
mRNA expression of the target genes of YAP: AmotL2 and CTGF. The mRNA levels of 
both genes were moderately higher at early time points compared to later when there is 
activation of YAP (Fig. 3, E and F). Taking the IHC and target gene expression data 
together, we concluded that YAP activity increases during initial time points up to 12 hr 
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after APAP overdose followed by a significant decrease. Because of the known role of 
YAP in proliferation and regulation of organ size as demonstrated by previous studies35, 
38, 51, we hypothesized that YAP activation would occur at later time points when the 
hepatic cells are proliferating and recovering. By contrast, YAP activation was seen 
when there is progression of injury.  
   
21 
 
Figure 3: Activation of YAP in APAP 300 
A-B: Bar graphs show % necrosis area based on H&E stained liver sections (A), total number of 
PCNA positive cells per five high power fields (B). C: Western blot analysis of total YAP and p-
YAP using total liver extract. D: Densitometric analysis shows active YAP, which is the ratio of 
total YAP to p-YAP. E-F: Bar graphs show mRNA expression of YAP target genes: AmotL2 (E) 





                         
Figure 4: YAP staining in APAP 300 
A: Representative photomicrographs of YAP-stained liver sections per five high power (40x) 
fields from mice treated with 300 mg/kg APAP. Arrowheads represent YAP positive cells 
(black: nuclear staining and yellow: cytoplasmic staining). 
23 
 
Characterization of hYAP-KO mice 
To further investigate the role of YAP in liver injury and regeneration following APAP 
overdose, we did additional studies in hYAP-KO model. Deletion of YAP was confirmed 
by Western blot analysis (Fig. 5A). The liver-to-body-weight ratio was not affected by 
YAP deletion (Fig. 5B). We measured serum ALT levels to determine whether deletion 
of YAP resulted in liver injury, which was normal in both the groups (Fig. 5C). 
Furthermore, hepatic CYP2E1 protein expression and total glutathione levels, both of 
which are the major components in APAP bioactivation process, were not changed 
between the groups (Fig. 5, D and E). These results suggest that the AAV8 virus is not 
causing liver injury and not is changing the components required for APAP 
bioactivation. Hence, the virus is experimentally good to use for hepatocyte specific 
YAP deletion.  
 
Kinetics of APAP-induced liver injury in hYAP-KO mice 
Next, we compared liver injury in two groups over the time course of 0-48 hours by 
determining the serum ALT activity level and histopathological analysis of liver sections 
(Fig. 6, A, B and C). The injury developed similarly in both groups until 12 hours after 
APAP treatment. However, liver injury in hYAP-KO mice decreased by 24 hours leading 
to almost complete recovery by 48 hours. The injury in control mice further progressed 
and increased at 24 hr. At 48 hr, liver injury declined in control mice as well but was 
significantly higher than the liver injury in hYAP-KO mice. These data indicate that 
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hepatocyte-specific YAP deletion leads to rapid regression of liver injury after APAP 
overdose.  
                     
 
Figure 5: Characterization of hYAP-KO mice 
A: Western blot analysis of YAP in Control (Ctrl) and YAP knockout (hYAP-KO) mice. B-C: Bar 
graphs show liver to body weight ratio (B) and Serum ALT level (C). D: Western blot analysis of 
CYP2E1 in Ctrl and hYAP-KO mice. E: Bar graph shows total glutathione (GSH+ GSSG) 
concentration in Ctrl and hYAP-KO mice. 
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Figure 6: Kinetics of APAP-induced liver injury in hYAP-KO mice 
A: Line graph show serum ALT level in Ctrl (black line) and hYAP-KO (gray line) mice treated 
with 300 mg/kg APAP. B: Representative photomicrograph of H&E stained liver sections from 
Ctrl and hYAP-KO mice treated with 300 mg/kg APAP with necrotic areas outlined.                   
C: Line graph shows % necrosis area based on H&E stained liver sections. *P<0.05 and 




Mechanism of decreased liver injury after APAP overdose in hYAP-KO mice 
We then looked into the components of APAP metabolism and injury pathway to 
understand the mechanism of the differences in liver injury in control and hYAP-KO 
mice. There was no significant difference in APAP-protein adducts between the groups 
at 1 and 12 hours after APAP treatment, suggesting that there is no difference in 
metabolic activation of APAP (Fig. 7A). The depletion of hepatic glutathione level from 0 
to 1 hour also indicated that there was no difference in APAP metabolism between the 
two groups. However, the recovery of glutathione was faster in hYAP-KO mice 
compared to control mice. GSH levels increased in both control and hYAP-KO mice but 
were significantly higher in hYAP-KO mice at 12 and 24 hours after APAP treatment 
(Fig. 7B). These data indicate that the early GSH replenishment in hYAP-KO mice could 
be the reason for the faster regression of injury in those mice. Previous studies have 
shown that RIP1 and RIP3 mediate hepatic injury after APAP overdose54, 55. In our 
studies, RIP1 level was similar in both control and hYAP-KO mice, while RIP3 level was 
higher in hYAP-KO mice at 1, 12 and 24 hours after APAP treatment (Fig. 7C). The 
activation of c-jun N-terminal kinase (JNK), as indicated by its phosphorylated form (p-
JNK), started at 1 hour in both groups. JNK activation remained higher until 12 hours 
after APAP treatment in hYAP-KO but was observed until 24 hr in the control mice (Fig. 
7D). These data indicate that YAP may be attenuating GSH recovery and also 
mediating JNK phosphorylation, which could be the reasons for decreased liver injury in 




                   
 
Figure 7: Mechanism of decreased liver injury after APAP overdose in hYAP-KO mice 
A: Bar graph shows APAP adduct in Ctrl (black bar) and hYAP-KO (gray bar) mice at 1 and 12 
hours after APAP 300 treatment. B: Line graph shows total glutathione (GSH+ GSSG) in Ctrl 
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(black line) and hYAP-KO (gray line) mice treated with 300 mg/kg APAP. C-D: Western blot 
analysis of RIP3 and RIP1 (C) and JNK and p-JNK (D) in Ctrl and hYAP-KO mice treated with 
300 mg/kg APAP. *P<0.05 and **P<0.001 between Ctrl and hYAP-KO group. 
 
Early induction of regenerative markers in hYAP-KO mice 
Next, we studied liver regeneration in control and hYAP-KO mice using PCNA analysis. 
The hepatic cells in hYAP-KO showed more proliferation at 24 hours after APAP 
treatment than the control mice, as indicated by PCNA positive cells around the necrotic 
areas. However, there was more proliferation in control mice than hYAP-KO mice at 48 
hours of APAP treatment (Fig. 8A). These data associated with the lower injury in 
hYAP-KO mice at 24 hours following APAP treatment (Fig. 6, A-B). We further studied 
expression of cell cycle proteins: Cyclin D1, CDK4 and p-Rb in the two groups. Cyclin 
D1 is the marker for cell cycle (G1 phase) progression. Cyclin D1 and CDK4 complexes 
phosphorylate Rb to overcome the late restriction checkpoint in the cell cycle56. Similar 
to the PCNA data, induction of Cyclin D1, CDK4 and p-Rb were higher in hYAP-KO 
mice than control mice at 24 hours, while these proteins were expressed more in control 
mice than hYAP-KO mice at 48 hours after APAP treatment (Fig. 8, B-D). These data 
suggest that hYAP-KO mice show an earlier onset of regeneration than control mice 
after APAP treatment.  
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Figure 8: Early induction of regenerative markers in hYAP-KO mice 
A: Representative photomicrograph of PCNA stained liver sections from Ctrl and hYAP- KO 
mice at 24 and 48 hours after APAP treatment. B-D: Western blot analysis of regenerative 
markers Cyclin D1, pRb and CDK4 in Ctrl and hYAP-KO mice during the time course (B), at 24 






Acetaminophen overdose is the most common cause of acute liver failure in the US2, 3. 
Treatment options for this drug-induced ALF are limited5-7.  A number of studies on 
chemicals and drugs that induce liver injury have shown that compensatory liver 
regeneration is the critical determinant of overall survival following APAP        
overdose19, 57, 58.  Several studies using animal models have shown that stimulating liver 
regeneration can be a potential treatment option for the APAP induced ALF21, 22. Herein, 
we studied the role of YAP, the downstream effector of the Hippo Kinase pathway, in 
liver injury and regeneration after APAP overdose.  
 YAP is involved in the regulation of organ size, hepatic differentiation and 
proliferation31, 35, 38, 51. Based on the known role of YAP, we hypothesized that activation 
of YAP would increase at the time points when the hepatic cells are proliferating and 
regenerating following APAP-induced acute liver injury. Thus, we investigated YAP 
activation in male C57BL/6J mice following 300 mg/kg of APAP. Unexpectedly, the 
activation of YAP was seen at earlier time points when there is progression of injury in 
hepatic cells while a decrease in YAP activation was observed during the regenerative 
phase post 24 hr. To further evaluate the role of YAP after APAP overdose, we did 
additional studies on hepatocyte-specific YAP-KO mice (hYAP-KO).  
 First, we looked at the injury level caused by APAP overdose in control and 
hYAP-KO mice. There was faster regression of injury in hYAP-KO mice. To understand 
the mechanism behind this faster recovery in hYAP-KO mice, we looked into several 
components of APAP metabolism pathway. There was no change in the APAP-protein 
adduct levels and the depletion of glutathione during the metabolism of APAP was 
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similar. This indicates that there is no difference in the bioactivation of APAP to its 
reactive metabolite NAPQI. However, the total hepatic glutathione level (GSH+GSSG) 
recovered faster in hYAP-KO mice. Glutathione is the major anti-oxidant that protects 
the liver from free radical injury. Increased oxidative stress in mitochondria during APAP 
toxicity is due to increased levels of peroxides and peroxynitrite. The superoxide formed 
during APAP toxicity is converted to hydrogen peroxide increasing oxidative stress. 
Glutathione is the cofactor for glutathione peroxidase, which detoxifies peroxides. 
Additionally, nitric oxide reacts with superoxide to form peroxynitrite, amplifying 
oxidative stress. Peroxynitrite is also detoxified by glutathione59. The higher glutathione 
level detoxifies the reactive oxygen species and the peroxynitrite radicals leading to 
reduced oxidative stress and lower injury. Hence, the faster recovery of glutathione in 
hYAP-KO mice could be the reason for the faster regression of injury in those mice.  
RIP1 and RIP3 proteins are involved in hepatic injury after APAP overdose54, 55. 
The RIP1 protein level was similar in the two groups, while the RIP3 level was higher in 
hYAP-KO mice where there is protection from injury. RIP3 regulates JNK activation and 
the mitochondrial oxidant stress54. Adduct formation is unchanged, while downstream 
mitochondrial dysfunction and oxidant stress is reduced in RIP3-deficient mice54. RIP3 
expression was higher in hYAP-KO mice in our study. However, the activation of JNK 
was higher and sustained longer in control mice as compared to the YAP KO mice.  
This shows that JNK activation is not regulated by RIP3 expression in hYAP-KO mice 
following APAP overdose.  
The activation of JNK amplifies mitochondrial oxidant stress and causes the 
formation of mitochondrial membrane permeability transition (MPT) pores, which are 
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responsible for the disruption of mitochondrial membrane permeability and cessation of 
ATP synthesis, ultimately leading to hepatic cell necrosis15. Thus, higher activation of 
JNK leads to higher injury. In our study, we observed a decrease in progression of injury 
in hYAP-KO mice, which was accompanied by an early decrease in JNK activation. 
However, the mechanism of how YAP regulates JNK remains to be elucidated. 
Interestingly, a previous study shows JNK1 and JNK2 act as YAP kinases, 
phosphorylating multiple sites on YAP60. The p-YAP is stabilized by binding to pro-
apoptotic transcription factor resulting in apoptosis60. Our study shows that YAP may be 
involved in liver injury following APAP overdose, which is a novel function of YAP. This 
seemingly contradictory role of YAP has been previously studied. Besides regulating 
growth, YAP also promotes apoptosis and is often used as chemotherapeutic target to 
induce cell-death in tumor-derived cell lines and as tumor suppressor in certain breast 
cancers61, 62. The contradictory function may be explained by YAP’s ability to bind to 
transcription factors other than TEAD, which can result in the activation of a different set 
of YAP target genes when compared to the ones we studied here. For example, the 
YAP- TEAD interaction promotes growth, while YAP binding to TAp73 signals 
apoptosis60. Whether or not this process occurs in our model, where there is necrotic 
cell death, remains to be studied. 
 Next, we studied liver regeneration in control and hYAP-KO mice following APAP 
overdose. A previous study has shown involvement of YAP in liver regeneration after 
PH35. However, in our study the hYAP-KO mice showed an earlier onset of regeneration 
than the control. The differences in the results may be due to inherent differences in 
models used to study liver regeneration. The APAP overdose has significant 
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mechanistic differences from the PH model. APAP overdose results in significant 
necrotic cell death and subsequent inflammation, both of which are minimal in PH63, 64. 
Additionally, liver regeneration is synchronous and involves proliferation of all the 
remaining hepatocytes in case of PH64. However, mostly the cells around the necrotic 
zones proliferate after APAP overdose22. Faster regeneration in hYAP-KO mice was 
most likely due to lower injury in those mice. There was an early induction of cyclin D1 
(which governs entry into cell cycle) in hYAP-KO mice. Cyclin D1 is one of the target 
genes of Wnt/β-catenin pathway; YAP inactivates β-catenin65. Similarly, the NF-B 
pathway is also activated during liver regeneration following APAP overdose, when the 
hepatic cells are less stressed22. Additionally, increased GSH levels is observed during 
proliferation of rat hepatocytes after PH. Increased GSH levels stimulates hepatocytes 
to shift from G0 to G1 phase of cell cycle66. In our study, we have observed increased 
levels of GSH in hYAP-KO mice. Thus, the early regeneration in hYAP-KO mice could 
be the result of increased activation of β-catenin and NF-B pathway or increased GSH 
levels. The increased proliferation in the control mice was observed at 48 hr because 
these mice are still recovering as shown by presence of necrotic foci, while the hYAP-
KO mice have almost completely recovered by this time. 
 Early regeneration in hYAP-KO mice may be due to decreased progression of 
injury or due to proliferative advantage of YAP-KO hepatocytes. To study this, we could 
perform an in vitro growth assay. Primary mouse hepatocytes could be isolated from 
control and hYAP-KO mice, without APAP treatment, and cultured in media with growth 
factors. Expression of several proliferative markers like PCNA, pRb, CDK4 and cyclins 
could be studied in the two groups at different time points (2, 4, and 6 days). If these 
35 
 
proliferative markers are induced early and higher in hYAP-KO mice, then it 
demonstrates that deleting YAP in hepatocytes helps the hepatocytes to enter the cell 
cycle and initiate proliferation.  
To further evaluate the role of YAP in liver injury and regeneration, C57BL/6J 
male mice could be treated with 300 mg/kg APAP with or without exposure to the YAP 
inhibitor, verteporfin. As shown earlier, regeneration starts in these mice at 12 hours 
after APAP administration (Fig. 3B). Thus, these mice are then treated with verteporfin, 
the chemical that disrupts the interaction between YAP and TEAD, around 10 hours 
following APAP administration and regeneration is studied. If proliferation is higher in 
verteporfin treated group, then it shows that disrupting YAP activity promotes 
proliferation of hepatocytes. Thus, if we observe higher proliferation after knocking out 
the YAP gene or disrupting YAP activity, then we could say that the early regeneration 
in hYAP-KO mice is due to the proliferative advantage of YAP-KO hepatocytes. 
However, if the proliferation is higher in the control group in both of the studies 
mentioned above, then the reason for early regeneration could be the decreased 
progression of injury in hYAP-KO mice where the hepatic cells are less stressed. In 
such case, other signaling pathways which are involved in proliferation may be activated 
in hYAP-KO mice.  
In summary, our findings indicate that deletion of YAP is associated with the 
protection of liver injury after APAP overdose. Faster regression of injury was observed 
after YAP deletion. This was followed by early regeneration in hYAP-KO mice as shown 
by an early induction of regenerative markers. Hence, YAP may serve as a potential 
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